ACTU.US Actuate Therapeutics, Inc. Common stock

Healthcare Biotechnology USA Stocks
0.2960 USD
Close of Nov 13, 2026
0.2900 7.90
Market cap
USD 16.3M
P/E
-
P/B
7.34x
ROE
-2,121.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ACTU.US undervalued?

Graham number

The Graham number of Actuate Therapeutics, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Actuate Therapeutics, Inc. Common stock fundamental analysis

No fundamental analysis for Actuate Therapeutics, Inc. Common stock yet.

Actuate Therapeutics, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neurobla…

Full company profile